Worldwide Healthcare (LON:WWH) Stock Price Down 0.3% – Should You Sell?

Worldwide Healthcare (LON:WWH)’s share price fell 0.3% on Monday . The company traded as low as GBX 331.50 ($4.23) and last traded at GBX 334 ($4.26). 1,004,572 shares were traded during trading, a decline of 20% from the average session volume of 1,251,930 shares. The stock had previously closed at GBX 335 ($4.27).

Worldwide Healthcare Trading Down 0.9 %

The company has a market cap of £1.77 billion, a PE ratio of -2,193.33 and a beta of 0.29. The company has a current ratio of 0.29, a quick ratio of 0.43 and a debt-to-equity ratio of 2.60. The business has a 50 day simple moving average of GBX 338.30 and a two-hundred day simple moving average of GBX 351.31.

Worldwide Healthcare Cuts Dividend

The firm also recently announced a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 28th will be given a dividend of GBX 0.70 ($0.01) per share. The ex-dividend date of this dividend is Thursday, November 28th. This represents a yield of 0.21%. Worldwide Healthcare’s dividend payout ratio (DPR) is presently -2,000.00%.

Insider Activity

In other Worldwide Healthcare news, insider William Hemmings bought 7,250 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average price of GBX 345 ($4.40) per share, with a total value of £25,012.50 ($31,907.77). Also, insider Sian Hansen purchased 3,017 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average price of GBX 330 ($4.21) per share, for a total transaction of £9,956.10 ($12,700.73). Corporate insiders own 0.41% of the company’s stock.

About Worldwide Healthcare

Worldwide Healthcare Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. The fund is managed by OrbiMed Capital LLC. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating in the healthcare sector, with an emphasis on pharmaceutical and biotechnology companies.